A single administration of combination therapy inhibits breast tumour progress bone and modifies both osteoblasts and osteoclasts

Journal of Bone Oncology

Volumn 1, Issue 2, 2012, Pages 47-56

  Brown, H K ^a   Ottewell, P D ^a   Evans, C A ^a   Coleman, R E ^a   Holen, I ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonate; Bone metastasis; Breast cancer; Combination therapy

Indexed keywords

DOXORUBICIN; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE TURNOVER; CELL COUNT; CELL PROLIFERATION; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 84877057540     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.05.001     Document Type: Article

References (35)

1. Brown HK, Holen I. Anti-tumour effects of bisphosphonates - what have we learned from in vivo models? Current Cancer Drug Targets 2009;9:807-23.
2. Syddall SP, Ottewell PD, Holen I. Combined therapies of bone disease with bisphosphonates. Current Pharmaceutical Design 2010;16:2988-97.
3. Brown HK, Ottewell PD, Evans CA, Holen I. Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clinical and Experimental Metastasis 2012.
4. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. The New England Journal of Medicine 1998;339:357-63. (Pubitemid 28363797)
5. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Annals of Oncology 2008;19:2007-11.
6. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. Journal of Clinical Oncology 2001;19:10-7. (Pubitemid 32063474)
7. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. The New England Journal of Medicine 2011;365:1396-405.
8. Santini D, Vincenzi B, Pantano F, Tonini G, Bertoldo F. Targeting bone metastases starting from the preneoplastic niche: home sweet home. Breast Cancer Research 2011;13:111.
9. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Research 2010;12:214.
10. van Beek ER, Lowik CW, van Wijngaarden J, Ebetino FH, Papapoulos SE. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease. Breast Cancer Research and Treatment 2009;118:307-13.
11. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006;6:15.
12. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. International Journal of Cancer 2010;126:522-32.
13. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. Journal of the National Cancer Institute 2008;100: 1167-78.
14. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Molecular Cancer Therapeutics 2009;8:2821-32.
15. Ottewell P, Brown H, Jones M, Rogers T, Cross S, Brown N, et al. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Research and Treatment 2011 [Epub ahead of print].
16. Ottewell PD, Deux B, Monkkonen H, Cross S, Coleman RE, Clezardin P, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clinical Cancer Research 2008; 14:4658-66.
17. Santini D, Pantano F, Vincenzi B, Tonini G, Bertoldo F. The role of bone microenvironment, vitamin D and calcium. Recent Results in Cancer Research 2012;192:33-64.
18. Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. Journal of Bone and Mineral Research 2010;25:2633-46.
19. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, et al. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Research 2009;69:5307-11.
20. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy Jr. JD, Evans HR, et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. Journal of Bone and Mineral Research 2009;24:425-36.
21. Mohanty ST, Kottam L, Gambardella A, Nicklin MJ, Coulton L, Hughes D, et al. Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis. Arthritis Research and Therapy 2010;12:R149.
22. van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CW, Wetterwald A, et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Research 2005;65:7682-90. (Pubitemid 41297242)
23. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, et al. Bispho-sphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research 1995;55:3551-7.
24. Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. International Journal of Cancer 1998;77:279-85. (Pubitemid 28287982)
25. Allen MR, Hock JM, Burr DB. Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 2004;35:1003-12. (Pubitemid 39487345)
26. Iwata K, Li J, Follet H, Phipps RJ, Burr DB. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 2006;39:1053-158.
27. Feher A, Koivunemi A, Koivunemi M, Fuchs RK, Burr DB, Phipps RJ, et al. Bisphosphonates do not inhibit periosteal bone formation in oestrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone 2010;46:203-7.
28. Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcified Tissue International 2008;82:191-201.
29. Orriss IR, Key ML, Colston KW, Arnett TR. Inhibition of osteoblast function in vitro by aminobisphosphonates. Journal of Cellular Biochemistry 2009;106:109-18.
30. Brown HK, Ottewell PD, Coleman RE, Holen I. The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. Journal of Cellular and Molecular Medicine 2011;15:501-13.
31. Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, et al. Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. Journal of Bone and Mineral Research 2009.
32. Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncology Reports 2006;15:1351-7.
33. Jain N, Weinstein RS. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nature Reviews Rheumatology 2009;5: 341-6.
34. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. The New England Journal of Medicine 2009;360:53-62.
35. Santini D, Virzi V, Fratto ME, Bertoldo F, Sabbatini R, Berardi R, et al. Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Current Cancer Drug Targets 2010;10:46-54.